| Literature DB >> 29451556 |
Romana Haneef1,2,3, Philippe Ravaud1,2,3,4,5, Gabriel Baron3, Lina Ghosn2, Isabelle Boutron1,2,3,4.
Abstract
BACKGROUND: New metrics have been developed to assess the impact of research and provide an indication of online media attention and data dissemination. We aimed to describe online media attention of articles evaluating cancer treatments and identify the factors associated with high online media attention.Entities:
Keywords: Altmetric score; Cancer treatment; Journal impact factor; Media attention; Open access; Press release
Year: 2017 PMID: 29451556 PMCID: PMC5803628 DOI: 10.1186/s41073-017-0033-z
Source DB: PubMed Journal: Res Integr Peer Rev ISSN: 2058-8615
Fig. 1Flow diagram of articles evaluating cancer treatments
General characteristics of articles
| Category | Total ( |
|---|---|
| Type of journal, | |
| − Cancer | 739 (93.3) |
| − General medical | 53 (6.7) |
| Journal impact factor, median [Q1–Q3] | 5.3 [4.8–16.4] |
| Study design | |
| − Systematic review/meta-analysis | 86 (10.9) |
| − Randomized controlled trial | 246 (31.1) |
| − Phase I/II, non-randomized trial | 113 (14.3) |
| − Observational study | 347 (43.8) |
| Cancer type by organ, | |
| − Digestive system | 168 (21.2) |
| − Breast | 135 (17.0) |
| − Lungs | 82 (10.4) |
| − Blood | 71 (8.9) |
| − Prostate | 53 (6.7) |
| − Female reproductive organ | 44 (5.6) |
| − Others | 239 (30.2) |
| Type of cancer treatment, | |
| − Chemotherapy | 212 (26.7) |
| − Targeted therapy | 88 (11.1) |
| − Radiotherapy | 69 (8.7) |
| − Surgery | 44 (5.5) |
| − Hormone therapy | 28 (3.5) |
| − Immunotherapy | 4 (0.5) |
| − Supportive care | 197 (25.0) |
| − Others | 150 (19.0) |
| Sample size, median [Q1–Q3]a | 181.0 [48.5–1010.5] |
| Type of abstract conclusion | |
| − In favour of study treatment | 523 (66.0) |
| − Not in favour of study treatment | 269 (34.0) |
| Funding source, | |
| − Non-profit | 418 (52.8) |
| − Profitb | 268 (33.8) |
| − Not reported | 106 (13.4) |
| Altmetric score, median [Q1–Q3] | 2.0 [0.0–8.0] |
| Open access | |
| − Yes | 462(58) |
| − No | 330(42) |
| Press-release | |
| − Yes | 56(7) |
| − No | 736(93) |
aExcluding the sample size of systematic reviews/meta-analyses
b12.2% is partially profit and non-profit
Fig. 2Distribution of Altmetric score for articles (n = 792) [Inset graph limited to articles with an Altmetric score ≤50]
Fig. 3Online media attention of articles by sources (n = 792)
Factors associated with online media attention (i.e., Altmetric score) of articles (n = 792)
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| RoM | 95%CI |
| RoM | 95%CI |
| ||
| Journal impact factor | (One unit) | 1.11 | [1.07–1.14] | <0.0001 | 1.10 | [1.07–1.12] | <0.0001 |
| Study design | • RCT vs observational study | 1.02 | [0.78–1.32] | 0.9259 | 0.65 | [0.41–1.02] | 0.0593 |
| • Phase I/II, non-randomized trial vs observational study | 0.46 | [0.34–0.62] | <0.0001 | 0.58 | [0.33–1.05] | 0.0715 | |
| • SR/MA vs observational study | 0.97 | [0.70–1.34] | 0.8381 | 1.46 | [0.74–2.86] | 0.2724 | |
| Abstract conclusion | In favour of study treatment (yes vs no) | 1.34 | [1.04–1.74] | 0.0254 | 0.97 | [0.60–1.58] | 0.9134 |
| Funding source | Non-profit vs for profit | 1.30 | [0.97–1.73] | 0.0773 | 1.45 | [1.08–1.94] | 0.0126 |
| Open access | Yes vs no | 1.72 | [1.27–2.33] | 0.0005 | 1.48 | [1.02–2.16] | 0.0418 |
| Press release | Yes vs no | 11.61 | [6.78–19.87] | <0.0001 | 10.14 | [4.91–20.96] | <0.0001 |
RoM ratio of mean
Mean, median and [min–max] for explanatory variables associated with Altmetric score (n = 792)
| Explanatory variables | Sub-categories | Mean (SD) | Median [Q1–Q3] | [Min–max] |
|---|---|---|---|---|
| Study design | SR/MA | 14.9 (37.0) | 3.5 [1.0–10.0] | [0.0–268.0] |
| RCT | 20.7 (50.5) | 3.0 [0.0–16.0] | [0.0–428.0] | |
| Phase I/II, non-RCT | 6.5 (17.2) | 2.0 [0.0–4.0] | [0.0–139.0] | |
| Observational study | 13.4 (39.7) | 2.0 [0.0–7.0] | [0.0–319.0] | |
| Abstract conclusion | In favour of study treatment | 16.6 (44.8) | 2.0 [0.0–9.0] | [0.0–428.0] |
| Not in favour of study treatment | 11.5 (32.5) | 2.0 [0.0–7.0] | [0.0–319.0] | |
| Funding source | Profit | 13.9 (41.1) | 2.0 [0.0–9.0] | [0.0–370.0] |
| Non-profit | 15.4 (41.1) | 2.0 [0.0–8.0] | [0.0–428.0] | |
| Open access | Yes | 17.9 (49.3) | 3.0 [1.0–8.0] | [0.0–428.0] |
| No | 10.6 (24.8) | 1.5 [0.0–8.0] | [0.0–258.0] | |
| Press release | Yes | 118.6 (87.5) | 84.5 [58.0–144.5] | [29.0–428.0] |
| No | 7.0 (19.0) | 2.0 [0.0–5.0] | [0.0–268.0] |
SR/MA systematic review/meta-analysis, RCT randomized controlled trial